GlassScriptPhysician profile
Alex A Yarbrough
NPI 1346253994
$9,360.94
in general payments reported to CMS, 2019-2025
42 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $201 · 2021: $250 · 2022: $1,364 · 2023: $2,241 · 2024: $1,674 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,085 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,085.10 |
| Education | $189.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,276.33 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $2,054.32 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $677.94 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $508.18 | 2019-2024 | |
| Medtronic, INC. | $375.93 | 2022-2023 | Pillcam |
| Merck Sharp & Dohme LLC | $370.92 | 2019-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $354.88 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $310.91 | 2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $295.44 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $234.57 | 2023 | Stelara |
| Celgene Corporation | $233.98 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $219.37 | 2019-2025 | |
| Olympus America INC. | $148.05 | 2024 | Endocapsule Recorder, Visiglide, Hanarostent Esophagus Tts(Ccc) |
| Abiomed | $145.93 | 2025 | |
| Endogastric Solutions, INC | $114.36 | 2023 | Esophyx |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Yarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.